Cancer and Cell Therapy · global
Helping T Cells Recognize Cancer and Resist Immune Suppression: University of Chicago Launches Solid Tumor Trial
This internally developed cell therapy modifies both T cells’ ability to recognize cancer and their mechanisms for resisting suppression, with plans to use it in advanced ovarian cancer and other solid tumors. A small early-stage trial will first assess safety, then look for signals of efficacy.
For immune cells to attack solid tumors, recognizing cancer cells alone is not enough; suppressive signals around tumors may also gradually weaken their ability to fight. UChicago Medicine announced the launch of a cell therapy trial that aims to address both challenges, saying it will begin screening eligible patients in October 2026. The announcement concerns the study’s launch; no human efficacy results are available yet.
This investigator-initiated Phase 1/2A trial uses patients’ own T cells, which are genetically modified and then infused back into their bodies. According to the institution, the cells will carry a T-cell receptor that recognizes NY-ESO-1, along with another modification that enables them to resist immune suppression caused by transforming growth factor beta (TGF-β). Researchers hope this will allow the cells to remain active longer within tumors.
The recognition mechanism also determines who may be eligible. Unlike CAR-T cells, which primarily recognize targets on the cell surface, this type of T-cell receptor therapy can recognize fragments derived from intracellular proteins and presented by HLA molecules. The trial registration therefore requires confirmation that patients’ tumors express NY-ESO-1 and that patients test positive for HLA-A*0201. Having a cancer type covered by the study does not necessarily mean a patient will qualify.
The treatment process also includes drugs. According to the institution, decitabine is used to increase NY-ESO-1 expression in tumors, while low-dose interleukin-2 helps the infused T cells proliferate and remain active. The registered protocol also lists cyclophosphamide pretreatment. The institution plans to infuse approximately one billion modified T cells per patient, but the trial includes safety assessments and provisions for dose reductions if needed. The actual dose used will still depend on how the study progresses.
The registration under NCT07389239 lists an anticipated enrollment of 24 participants and an open-label, nonrandomized design, beginning with a safety lead-in phase before expanding separately to patients with ovarian cancer and those with other solid tumors. In addition to recording treatment-related adverse events, the study will track the persistence of the modified cells in the body, objective tumor responses, and progression-free survival. However, the ICH GCP mirror page reflects a February 2026 update and still lists the study as not yet recruiting, so it cannot establish the real-time enrollment status following the October announcement.
Another distinctive feature is the manufacturing process. The institution says this is the first time the center has kept the design, manufacturing, and administration of an experimental cell therapy entirely on campus, with production taking place in a facility that complies with good manufacturing practice (GMP). Richard Koya developed the therapy, Daniel Olson leads the clinical trial, and Thinle Chodon oversees cell manufacturing. This arrangement gives the research team direct oversight of every step, from cell preparation to clinical use.
The study will next seek to determine whether the dual modifications can function safely in humans and whether cell persistence is accompanied by measurable tumor responses. Given the small number of participants, the lack of a randomized control group, and the combination of multiple interventions, even preliminary responses would make it difficult to determine the contribution of each modification separately and would be insufficient to establish superiority over existing treatments. For advanced solid tumors, this is a clinical exploration based on a clear mechanistic hypothesis, with some way still to go before durable efficacy can be demonstrated.